Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Accumulated Expenses (2020 - 2026)

Xeris Biopharma Holdings filings provide 6 years of Accumulated Expenses readings, the most recent being $33.2 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 19.62% to $33.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.2 million, a 19.62% increase, with the full-year FY2025 number at $33.2 million, up 19.62% from a year prior.
  • Accumulated Expenses hit $33.2 million in Q4 2025 for Xeris Biopharma Holdings, up from $30.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $49.1 million in Q4 2021 to a low of $19.1 million in Q3 2023.
  • Median Accumulated Expenses over the past 5 years was $24.3 million (2024), compared with a mean of $28.1 million.
  • Biggest five-year swings in Accumulated Expenses: surged 208.83% in 2021 and later crashed 49.42% in 2023.
  • Xeris Biopharma Holdings' Accumulated Expenses stood at $49.1 million in 2021, then decreased by 25.06% to $36.8 million in 2022, then crashed by 36.09% to $23.5 million in 2023, then increased by 17.89% to $27.7 million in 2024, then grew by 19.62% to $33.2 million in 2025.
  • The last three reported values for Accumulated Expenses were $33.2 million (Q4 2025), $30.4 million (Q3 2025), and $25.0 million (Q2 2025) per Business Quant data.